Stock Events

Stock Events

Dermata Therapeutics 

$0.000600
18
+$0.00+0% Monday 15:49
+$0.00+0%Monday 20:00After hours

Statistics

Day High
0.0011
Day Low
0.0005
52W High
0.0011
52W Low
0.0005
Volume
146,059
Avg. Volume
-
Mkt Cap
2,973.12
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-4.5
-3.16
-1.82
-0.48
Expected EPS
-0.55
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-7.56MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow DRMAW. It's not an investment recommendation.
NVIDIA
4
NVDA
SoundHound AI
4
SOUN
Apple
3
AAPL
Microsoft
3
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Aclaris Therapeutics
ACRS
Mkt Cap884.67M
Aclaris Therapeutics focuses on dermatological treatments, directly competing in Dermata's market space for skin conditions.
AnaptysBio
ANAB
Mkt Cap1.67B
AnaptysBio is involved in developing therapeutic antibodies for inflammatory diseases, including dermatological conditions, making it a direct competitor.
Journey Medical
DERM
Mkt Cap210.84M
Journey Medical Corporation, operating under the ticker DERM, focuses on dermatology, competing in the same therapeutic areas as Dermata.
Sol-Gel Technologies
SLGL
Mkt Cap225.28M
Sol-Gel Technologies develops dermatology products, including for acne and rosacea, directly competing with Dermata's product pipeline.
Moderna
MRNA
Mkt Cap55.09B
Moderna, known for its mRNA technology, is exploring dermatological applications, potentially competing with Dermata in innovative treatments.
Biomarin Pharmaceutical
BMRN
Mkt Cap12.52B
BioMarin Pharmaceutical, while focusing on genetic diseases, has interests in skin-related treatments, posing indirect competition.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals, with its broad focus on biopharmaceuticals, includes dermatology in its portfolio, competing on some fronts with Dermata.
Pfizer
PFE
Mkt Cap159.36B
Pfizer, a large pharmaceutical company, has a diverse portfolio that includes dermatology, making it a competitor on a broader scale.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its Janssen Pharmaceuticals division, offers products for skin health, competing across several dermatological areas.

About

Dermata Therapeutics Inc develops and commercializes dermatology products for the treatment of common skin conditions. It focuses on leveraging prior clinical and technical expertise to develop OTC treatments for conditions such as acne, psoriasis, rosacea, and seborrheic dermatitis. The company is currently developing a once-weekly acne treatment system that utilizes an active ingredient from the OTC monograph in combination with the company's Spongilla technology. It intends to apply its Spongilla technology platform across a range of dermatologic and aesthetic skin applications, including intradermal delivery of botulinum toxin. The company's operates in one segment, which is the business of developing, branding, marketing, and commercializing direct to consumer skincare products.
Show more...
CEO
Gerald T. Proehl
Employees
9
Country
United States
ISIN
US2498451168

Listings

BOATS
BOATS
DRMA.BOATS
XNAS
US
DRMA
XNAS
US
DRMAW

0 Comments

Share your thoughts

FAQ

What is Dermata Therapeutics stock price today?▼
The current price of DRMAW is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Dermata Therapeutics stock price performance more closely on the chart.
What is Dermata Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Dermata Therapeutics stocks are traded under the ticker DRMAW.
What is Dermata Therapeutics market cap?▼
Today Dermata Therapeutics has the market capitalization of 2,973.12
When is the next Dermata Therapeutics earnings date?▼
Dermata Therapeutics is going to release the next earnings report on November 18, 2026.
What were Dermata Therapeutics earnings last quarter?▼
DRMAW earnings for the last quarter are -0.74 USD per share, whereas the estimation was -0.55 USD resulting in a -34.55% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Dermata Therapeutics revenue for the last year?▼
Dermata Therapeutics revenue for the last year amounts to 0 USD.
What is Dermata Therapeutics net income for the last year?▼
DRMAW net income for the last year is -7.56M USD.
How many employees does Dermata Therapeutics have?▼
As of September 04, 2026, the company has 9 employees.
In which sector is Dermata Therapeutics located?▼
Dermata Therapeutics operates in the Health & Wellness sector.
When did Dermata Therapeutics complete a stock split?▼
The last stock split for Dermata Therapeutics was on August 01, 2025 with a ratio of 1:10.
Where is Dermata Therapeutics headquartered?▼
Dermata Therapeutics is headquartered in SAN DIEGO, United States.